solutions, suspensions, emulsions, and lyophilized products.

3. Responsibilities

• Formulation Development Team: Identify, justify, and document excipient selection.
• Analytical Development: Evaluate stability and compatibility of excipients with API.
• QA: Review selection rationale and ensure compliance with regulatory guidelines.

4. Accountability

The Head – Product Development and Head – QA are accountable for ensuring that excipient selection is scientifically justified and documented.

5. Procedure

5.1 Preliminary Considerations

• Assess the purpose of each excipient (e.g., solubilizer, buffer, antioxidant, stabilizer, tonicity agent, preservative).
• Ensure all selected excipients are approved for parenteral use and listed in pharmacopeias (USP, Ph. Eur., IP, etc.).
• Check compliance with IIG (Inactive Ingredient Guide) or JPE where applicable.

5.2 Excipient-API Compatibility

1. Perform compatibility studies under accelerated conditions (40°C/75% RH, 60°C dry).
2. Use analytical techniques such as HPLC, FTIR, DSC to identify potential interactions.
3. Document results in Excipient Compatibility Report (Annexure-1).

5.3 Functional Evaluation

1. For buffers, confirm suitable pKa range and buffering capacity.
2. For solubilizers (e.g., PEG, polysorbates), validate concentration-effect curves.
3. For lyoprotectants and cryoprotectants, validate freeze-thaw and lyophilization profiles.

5.4 Toxicological and Safety Review

• Review literature and toxicological data for maximum allowable daily intake (ADI).
• Ensure selected concentration is well within safety margins.
• Check for hypersensitivity or contraindications relevant to target population.

5.5 Regulatory Compliance

• Ensure excipients meet pharmacopeial monograph specifications and are of injectable grade.
• Maintain vendor CoA, DMF availability (where applicable), and GMP compliance documentation.

5.6 Documentation

• Complete Excipient Selection Justification Form (Annexure-2).
• Maintain records in formulation development file with version control.

6. Abbreviations

• API: Active Pharmaceutical Ingredient
• IIG: Inactive Ingredient Guide
• DSC: Differential Scanning Calorimetry
• FTIR: Fourier-Transform Infrared Spectroscopy

7. Documents

1. Excipient Compatibility Report – Annexure-1
2. Excipient Selection Justification Form – Annexure-2
3. Reference Pharmacopeial Monographs – Annexure-3

8. References

• FDA Guidance: Inactive Ingredient Database
• ICH Q8 – Pharmaceutical Development
• USP/NF Monographs

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Formulation Scientist	QA Executive	Head QA
Department	Product Development	Quality Assurance	Quality Assurance

11. Annexures

Annexure-1: Excipient Compatibility Report

Includes results from accelerated stability testing and analytical profiling with the API.

Annexure-2: Excipient Selection Justification Form

Excipient Name	Function	Concentration (%)	Rationale	Parenteral Approval
Sodium Chloride	Tonicity Agent	0.9	Maintain isotonicity	Yes (USP)

Annexure-3: Reference Pharmacopeial Monographs

• Monograph printouts or links for each excipient included in formulation.

Revision History

Revision Date	Revision No.	Details	Reason	Approved By
01/12/2022	1.0	Initial version	New SOP	Head QA
18/06/2025	2.0	Expanded documentation and added justification tables	GMP harmonization	Head QA